长链非编码RNA LINC00342通过靶向miR-384促进肾透明细胞癌细胞的增殖、侵袭和迁移

Long non-coding RNA LINC00342 promotes the proliferation, invasion, and migration of clear cell cancer renal cell carcinoma cells by targeting miR-384

Objective To investigate the role of long non-coding RNA (LncRNA) LINC00342 in clear cell renal cell carcinoma (ccRCC) and its mechanism. Methods The expression levels of LINC00342 in ccRCC tissues were analyzed by the GEPIA database. The expression levels of LINC00342 in ccRCC tissues and ccRCC cell lines were detected by qRT-PCR and and its correlation with the clinicopathological characteristics of patients were analyzed. The effects of LINC00342 on ccRCC cell proliferation, migration and invasion were verified by CCK8 assay, scratch healing assay and Transwell invasion assay. The expression of proteins involved in the Epithelial-mesenchymal transition (EMT) pathway were determined by Western blot assay. The target genes of LINC00342 were predicted by bioinformatics, and the targeting relationship of LINC00342 and miR-384 was validated by dual-luciferase reporter gene assay. Results The analysis of the GEPIA database showed that LINC00342 was highly expressed in ccRCC tissues and that the expression levels were negatively correlated with overall survival rate(all P<0.05). The qRT-PCR results showed that the expression levels of LINC00342 were significantly increased in both ccRCC tissues and ccRCC cells (all P<0.05).The high expression of LINC00342 was positively correlated with tumor size and stage (all P<0.05). Downregulation of LINC00342 expression inhibited the proliferation, migration and invasion of ccRCC cells (all P<0.05). Silencing of LINC00342 downregulates Vimentin and N-cadherin expression and upregulates E-cadherin expression (all P<0.05). Bioinformatic analysis revealed the presence of a miR-384 binding site to LINC00342, and the results of dual-luciferase reporter gene assay indicate that miR-384 is one of the downstream target genes of LINC00342. Conclusions LINC00342 promotes the malignant phenotype and EMT progression of ccRCC by targeting miR-384.